<DOC>
	<DOCNO>NCT00562588</DOCNO>
	<brief_summary>German stroke unit hesitate use Aggrenox secondary ischaemic stroke / transient ischaemic attack ( TIA ) prevention sub-acute treatment set . They argue clinical experience sub-acute Aggrenox treatment limit poorly document compare sub-acute acetylsalicylic acid ( ASA ) treatment . However , long term treatment ( start 3-6 month stroke/TIA ) Aggrenox safe superior ASA treatment prevent recurrent stroke . There evidence ASA prevent neurological progression stroke first 3 month . Results cohort study suggest start Aggrenox within 72 hour stroke predicts clinical improvement National Institute Health Stroke Scale ( NIHSS ) discharge hospital . Dipyridamole suppress acute inflammatory response stroke . This study design investigate tolerability efficacy secondary stroke prevention treatment Aggrenox initiate within 24 hour stroke onset stroke unit compare later initiation 7 day ASA treatment outside stroke unit setting .</brief_summary>
	<brief_title>EARLY 3-months Aggrenox Treatment Started Within 24 Hrs Ischemic Stroke Onset vs. After One Week 100 mg ASA</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Aspirin , Dipyridamole Drug Combination</mesh_term>
	<criteria>Clinical diagnosis ischaemic stroke cause measurable neurological deficit define impairment language , motor function , cognition and/or gaze , vision neglect . Symptoms must distinguishable episode generalise ischaemia ( i.e . syncope ) , seizure , migraine disorder . Main inclusion criterion : Patients risk stroke transient ischaemia brain complete ischaemic stroke due thrombosis Symptoms ischaemic attack begin less 24 hour prior study medication start , present least 30 minute significantly improve start treatment Patients eligible platelet inhibit treatment National Institute Health Stroke Scale ( NIHSS ) 5 20 ( prescreening screen ) Actual Modified Rankin Scale ( mRS ) ( baseline ) worse retrospective mRS ( stroke ) A contraindication stroke lysis give Patients able give ( least oral ) inform consent swallow either medication Hypersensitivity component product salicylate . Patients active gastric duodenal ulcer bleed disorder . Pregnancy third trimester . Lysis therapy . A platelet inhibit therapy Acetylsalicylic Acid ( ASA ) dose 100 mg per day , clopidogrel dose plan start . Time onset stroke symptom unknown ( stroke happen night/sleeping time , bedtime assumed time onset )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>